BCL2L1 and colorectal carcinoma: Since we demonstrate that MCL1 and Bcl-xL are frequently co-expressed at high levels in late-stage CRC patients, combining DNA damaging agents with selective Bcl-xL inhibitors may represent a tractable therapeutic strategy for treating this devastating disease.